N/A
N=242
INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus
Carcinoma, Renal Cell · Lymphoma, Mantle-Cell
Bottom Line
View on ClinicalTrials.gov: NCT01367457 ↗Enrolled (actual)
242
Serious AEs
11.6%
Results posted
Apr 2016
Primary outcome: Primary: Progression-free Survival (PFS) — 4.04; 7.467; 13.233 months
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Temsirolimus (Non-Interventional Study) (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Pfizer
- Primary completion
- Apr 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression-free Survival (PFS) |
4.04; 7.467; 13.233 | — |
| PRIMARY Percentage of Participants With Objective Response |
0.5; 34.8; 30.8; 14.3; 17.4; 50.0 | — |
| PRIMARY Duration of Response (DOR) |
13.21; 7.28; 8.82 | — |
| PRIMARY Overall Survival (OS) |
10.81; 19.233; 18.667 | — |
| PRIMARY Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) |
145; 19; 16; 18; 3; 7 | — |
Summary
The principal objective of the study is to evaluate the efficacy and safety of temsirolimus use in patients with Renal Cell Carcinoma and Mantle Cell Lymphoma.
Eligibility Criteria
Inclusion Criteria
Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.
Exclusion Criteria
Patients that do not have a minimum (pre-specified) of data in their clinical record.
Data sourced from ClinicalTrials.gov (NCT01367457). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.